CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,244,783
- in 2 filings, $3.2M under 10b5-1 plans
Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-18 | Nichols William Garrett Chief Medical Officer | Option exercise 10b5-1 | +4,584 | $3.75 | $17K | 83,904 |
| 2025-03-18 | Nichols William Garrett Chief Medical Officer | Option exercise 10b5-1 | +13,905 | $1.29 | $18K | 97,809 |
| 2025-03-18 | Nichols William Garrett Chief Medical Officer | Sale 10b5-1 | −45,316 | $8.76 | $397K | 52,493 |
| 2025-03-18 | Nichols William Garrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,584 | 195,416 | ||
| 2025-03-18 | Nichols William Garrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −13,905 | 31,095 | ||
| 2025-03-18 | Barone Francesca Chief Scientific Officer | Option exercise 10b5-1 | +18,000 | $1.55 | $28K | 128,673 |
| 2025-03-18 | Barone Francesca Chief Scientific Officer | Sale 10b5-1 | −32,146 | $8.76 | $282K | 96,527 |
| 2025-03-18 | Barone Francesca Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,000 | 30,822 | ||
| 2025-03-18 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −25,772 | $8.77 | $226K | 226,140 |
| 2025-03-17 | Tyagarajan Seshu Chief Technology Officer | Option exercise 10b5-1 | +20,000 | $1.29 | $26K | 116,790 |
| 2025-03-17 | Tyagarajan Seshu Chief Technology Officer | Sale 10b5-1 | −31,278 | $8.82 | $276K | 85,512 |
| 2025-03-17 | Tyagarajan Seshu Chief Technology Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 70,000 | ||
| 2025-03-17 | Tyagarajan Seshu Chief Technology Officer | Sale 10b5-1 | −31,278 | $8.82 | $276K | 85,512 |
| 2025-03-17 | Tyagarajan Seshu Chief Technology Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 70,000 | ||
| 2025-03-17 | Schoch Charles See Remarks | Sale 10b5-1 | −5,000 | $8.83 | $44K | 38,038 |
| 2025-02-21 | Aguilar-Cordova Estuardo 10% owner | Returned to the company | −10,582 | $12.02 | $127K | 120,861 |
| 2025-02-21 | Aguilar-Cordova Estuardo 10% owner | Returned to the company | −10,583 | $12.02 | $127K | 162,929 |
| 2025-02-12 | Tyagarajan Seshu Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-02-12 | Schoch Charles See Remarks | Grant or award · Stock Option (Right to Buy) | +83,000 | 83,000 | ||
| 2025-02-12 | Nichols William Garrett Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +107,250 | 107,250 |
Page 4 of 13 · 249 trades